Theravance Biopharma, Inc. (NASDAQ:TBPH) is reporting third quarter earnings results on Thursday 5th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.97 per share.
For the full year, analysts predict revenues of $ 81.60 million, while looking forward to loss of $ 4.07 per share.
Previous Quarter Performance
Theravance Biopharma, Inc. communicated loss for the second quarter of $ 1.00 per share, from the revenue of $ 15.01 million. The quarterly revenues declined 42.60 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.98 per share from $ 19.64 million in revenue. The bottom line results missed street analysts by $ 0.02 or 2.04 percent, at the same time, top line results fell short of analysts by $ 4.63 million or 23.57 percent.
Stock Performance
Shares of Theravance Biopharma, Inc. traded up $ 0.55 or 2.92 percent on Wednesday, reaching $ 19.38 with volume of 223.10 thousand shares. Theravance Biopharma, Inc. has traded high as $ 20.02 and has cracked $ 18.52 on the downward trend
The closing price of $ 19.38, representing a 30.04 % increase from the 52 week low of $ 14.48 and a 40.3 % decrease over the 52 week high of $ 31.54.
The company has a market capital of $ 1.23 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 14th October 2020, upgraded by Morgan Stanley to Overweight from Equal-Weight rating.
Conference Call
Theravance Biopharma, Inc. will be hosting a conference call at 5:00 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.theravance.com
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant. YUPELRI, a long-acting muscarinic antagonist, for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD); and Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders.
